IP Library Granted Patent US 11,326,160
Granted Patent B2
US 11,326,160 · App. 16/892,087 · Granted May 10, 2022

Method for making a cDNA library

Inventors: Kevin Allen (Austin, TX); Adam Morris (Red Rock, TX)
Assignee: BIOO SCIENTIFIC CORPORATION
C12N15/1096
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,326,160
App. No.
16/892,087
Granted
May 10, 2022
Kind
B2
Abstract

This disclosure provides, among other things, a method for making a cDNA library. In some embodiments the method may comprise reverse transcribing mRNA to produce DNA:mRNA hybrids, treating the DNA:mRNA hybrids with RNAseH to produce mRNA fragments, and reverse transcribing the mRNA fragments.

Claims (19)

1. A reagent system for producing cDNA comprising:

(a) a first oligod(T) primer;

(b) a reverse transcriptase that has been engineered to remove intrinsic RNAseH activity;

(c) an RNaseH; and

(d) a poly(A) polymerase

(e) a second oligod(T) primer, wherein the second oligod(T) primer comprises a 5′ tail.

2. The system of claim 1 , wherein the system further comprises:

(f) a 5′ adapter.

3. The system of claim 2 , further comprising:

(g) an RNA ligase.

4. The system of claim 1 , wherein the first oligod(T) primer is an anchored oligo(dT) primer.

5. The system of claim 1 , wherein the first oligod(T) primer does not have a 5′ tail.

6. The system of claim 5 , wherein the system further comprises:

(f) a 5′ adapter; and

(g) an RNA ligase.

7. The system of claim 6 , wherein the system further comprises:

(h) a pair of PCR primers, wherein the pair of PCR primers comprises a first primer that hybridizes to the 5′ tail of the second oligod(T) primer and a second primer that hybridizes to the complement of the 5′ adapter.

8. The system of claim 1 , wherein at least one of (b), (c) and (d) is in a composition that further comprises a non-naturally occurring buffering agent.

9. The system of claim 8 , wherein the non-naturally occurring buffering agent is Tris, HEPES, TAPS, MOPS, tricine or MES.

Assignments (2)
MERGER Recorded Jan 19, 2026
From: BIOO SCIENTIFIC CORPORATION
To: REVVITY HEALTH SCIENCES, INC.
Reel/Frame 073506/0008 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2020
From: ALLEN, KEVIN; MORRIS, ADAM
To: BIOO SCIENTIFIC CORPORATION
Reel/Frame 052830/0743 →
Continuity (2)
Continuation 15818469 · Nov 20, 2017
Related Publication 20200291393A1 · Sep 17, 2020